Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. (2020)

First Author: Lochhead P
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.52050

Publication URI: https://www.repository.cam.ac.uk/handle/1810/304969

Type: Journal Article/Review